EMA Lays Out Plans For Routine Use Of Real-World Evidence
EU Draft Artificial Intelligence Guideline Slated For November 2022
A panel of regulators overseeing the implementation of several big data projects within the EU medicines network has given details of real-world evidence integration pilots to be undertaken next year by various European Medicines Agency scientific committees.
You may also be interested in...
An EU review shows the great potential of regulator-led real-world evidence studies to address a range of research questions for regulatory decision making. It also provides learnings and recommendations for future improvements to the RWE framework being drawn up by the European Medicines Agency alongside the European medicines regulatory network.
A two-year pilot will explore the many potential benefits that the analysis of raw data can bring to the EU drug evaluation process. These range from faster patient access to medicines, companies facing fewer questions, and better definition of the target treatment population.
An EU-wide network of real-world data sources will aim to become the dominant vehicle for delivering such evidence to the EMA and member countries, who have until now been using a wide range of different sources to access such data.